“Increasing Adoption of Non-invasive Ventilation (NIV) in Treatment”
One specific trend driving growth in the infantile apnea drugs market is the increasing adoption of non-invasive ventilation (NIV) methods. NIV devices, such as nasal continuous positive airway pressure (CPAP), are becoming more widely used to manage infantile apnea. These devices help infants maintain adequate oxygen levels without the need for invasive procedures, reducing the risk of complications. The growing preference for less invasive treatments and technological advancements in NIV devices are contributing to a positive market outlook. For instance, the launch of improved CPAP systems for neonates has significantly boosted demand for infantile apnea drugs, as these devices often work in conjunction with pharmacological treatments to enhance outcomes.
